期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

NLRP3炎症小体对肾脏疾病的作用研究进展 被引量：7

Research Progress in the Role of NLRP3 Inflammasome in Renal Diseases
下载PDF
导出
摘要 NLRP3炎症小体是一种多蛋白复合体,在肾脏相关疾病中发挥致炎作用,本文旨在探讨NLRP3炎症小体在肾脏疾病中激活的机制及其在肾脏疾病发展中起到的作用,进一步清晰地认识到NLRP3炎症小体与肾脏疾病的联系,指导药物的开发和应用。 NLRP3 inflammasome is a multi-protein complex that plays a role in the inflammation of kidney-related diseases.The article aimed to investigate the activation mechanism of NLRP3 inflammasome in kidney diseases and its role in the development of kidney diseases to further recognize the link between NLRP3 inflammasome and kidney diseases clearly,and guide the development and application of drugs.
作者 陈林 许欢 邢莎莎 曾琦纹 杨亚飞 刘俊莹 杨德华 Chen Lin;Xu Huan;Xing Shasha;Zeng Qiwen;Yang Yafei;Liu Junying;Yang Dehuac(Department of Urology Affiliated Hospital of Chengdu University,Chengdu 610081,China;2.Central Laboratory Affiliated Hospital of Chengdu University,Chengdu 610081,China;3.Drug Clinical Trial Center,Affiliated Hospital of Chengdu University,Chengdu 610081,China)
机构地区 成都大学附属医院泌尿外科 成都大学附属医院中心试验室 成都大学附属医院药物临床实验中心
出处 《中国药师》 CAS 2018年第12期2218-2223,共6页 China Pharmacist
关键词 肾脏疾病 NLRP3炎症小体 致炎作用 Kidney diseases NLRP3 inflammasome Inflammatory effects
分类号 R692 [医药卫生—泌尿科学]
  • 相关文献

参考文献4

二级参考文献191

  • 1AIborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249-55.
  • 2Kang OH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002; 13: 806-16.
  • 3Gadola L, Noboa O, Marquez MN, Rodriguez M J, Nin N, Boggia J, et al. Calcium citrate ameliorates the progression of chronic renal injury. Kidney Int 2004; 65: 1224-30.
  • 4Vasquez J, Mathison Y, Romero-Vecchione E, Suarez C. Effect of sulodexide on aortic vasodilation capacity and associated morpho- logical changes in rats with streptozotocin-induced diabetes. Invest Clin 2010: 51: 467-77.
  • 5Ceol M, Gambaro G, Sauer U, Baggio B, Anglani F, Forino M, et al. Glycosaminoglycan therapy prevents TGF-betal overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephro12000; 11: 2324-36.
  • 6Shah SV. Progress toward novel treatments for chronic kidney disease. J Ren Nutr 2010; 20- S122-6.
  • 7Cirujeda JL, Granado PC. A study on the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis. Angiology 2006; 57: 53- 64.
  • 8Coccheri S, Scondotto G, Agnelli G, Aloisi D, Palazzini E, Zamboni V, et al. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost 2002: 87: 947-52.
  • 9Karorn J, Potubinska A, Antoniewicz AA, Sumirnska-Jasirnska K, Breborowicz A. Anti-inflammatory effect of sulodexide during acute peritonitis in rats. Blood Purif 2007; 25: 510-4.
  • 10Fracasso A, Baggio B, Masiero M, Bonfante L, Bazzato G, Feriani M, et al. Effect of oral treatment with the glycosaminoglycan sulodexide on peritoneal transport in CAPD patients. Perit Dial Int 2003; 23: 595-9.

共引文献71

同被引文献84

引证文献7

二级引证文献31

中国药师
2018年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部